Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease

Long-Huan Zeng,1,* Yi-Xin Hu,2,* Lin Liu,2 Meng Zhang,1 Hua Cui1 1Second Geriatric Cardiology Division, 2Clinical Department of Geriatrics, Chinese PLA General Hospital, Beijing, People's Republic of China *These authors contributed equally to this work Purpose: This study was undertaken to...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zeng LH, Hu YX, Liu L, Zhang M, Cui H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	β2-agonists β-blockers the β-blockers-β2-agonists combination COPD cardiac function mortality Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/f98dddf93a9643b5b7e1aa61c245f768
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f98dddf93a9643b5b7e1aa61c245f768
record_format	dspace
spelling	oai:doaj.org-article:f98dddf93a9643b5b7e1aa61c245f7682021-12-02T07:15:44ZImpact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease1178-1998https://doaj.org/article/f98dddf93a9643b5b7e1aa61c245f7682013-09-01T00:00:00Zhttps://www.dovepress.com/impact-of-beta2-agonists-beta-blockers-and-their-combination-on-cardia-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Long-Huan Zeng,1,* Yi-Xin Hu,2,* Lin Liu,2 Meng Zhang,1 Hua Cui1 1Second Geriatric Cardiology Division, 2Clinical Department of Geriatrics, Chinese PLA General Hospital, Beijing, People's Republic of China *These authors contributed equally to this work Purpose: This study was undertaken to determine the association between cardiac function and therapy with beta2-adrenoceptor agonists (β2-agonists), β-blockers, or β-blocker–β2-agonist combination therapy in elderly male patients with chronic obstructive pulmonary disease (COPD). Patients and methods: This was a retrospective cohort study of 220 elderly male COPD patients (mean age 84.1 ± 6.9 years). The patients were divided into four groups on the basis of the use of β-blockers and β2-agonists. N-terminal fragment pro-B-type natriuretic peptide (NT pro-BNP), left ventricular ejection fraction (LVEF), and other relevant parameters were measured and recorded. At follow-up, the primary end point was all-cause mortality. Results: Multiple linear regression analysis revealed no significant associations between NT pro-BNP and the use of β2-agonists (β = 35.502, P = 0.905), β-blockers (β = 3.533, P = 0.989), or combination therapy (β = 298.635, P = 0.325). LVEF was not significantly associated with the use of β2-agonists (β = −0.360, P = 0.475), β-blockers (β = −0.411, P = 0.284), or combination therapy (β = −0.397, P = 0.435). Over the follow-up period, 52 patients died, but there was no significant difference in mortality among the four groups (P = 0.357). Kaplan–Meier analysis showed no significant difference among the study groups (log-rank test, P = 0.362). After further multivariate adjustment, use of β2-agonists (hazard ratio [HR] 0.711, 95% confidence interval [CI] 0.287–1.759; P = 0.460), β-blockers (HR 0.962, 95% CI 0.405–2.285; P = 0.930), or combination therapy (HR 0.638, 95% CI 0.241–1.689; P < 0.366) were likewise not correlated with mortality. Conclusion: There was no association between the use of β2-agonists, β-blockers, or β-blocker–β2-agonist combination therapy with cardiac function and all-cause mortality in elderly male COPD patients, which indicated that they may be used safely in this population. Keywords: β2-agonists, β-blockers, β-blocker–β2-agonist combination, elderly COPD patients, cardiac function, mortalityZeng LHHu YXLiu LZhang MCui HDove Medical Pressarticleβ2-agonistsβ-blockersthe β-blockers-β2-agonists combinationCOPDcardiac functionmortalityGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 8, Pp 1157-1165 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	β2-agonists β-blockers the β-blockers-β2-agonists combination COPD cardiac function mortality Geriatrics RC952-954.6
spellingShingle	β2-agonists β-blockers the β-blockers-β2-agonists combination COPD cardiac function mortality Geriatrics RC952-954.6 Zeng LH Hu YX Liu L Zhang M Cui H Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease
description	Long-Huan Zeng,1,* Yi-Xin Hu,2,* Lin Liu,2 Meng Zhang,1 Hua Cui1 1Second Geriatric Cardiology Division, 2Clinical Department of Geriatrics, Chinese PLA General Hospital, Beijing, People's Republic of China *These authors contributed equally to this work Purpose: This study was undertaken to determine the association between cardiac function and therapy with beta2-adrenoceptor agonists (β2-agonists), β-blockers, or β-blocker–β2-agonist combination therapy in elderly male patients with chronic obstructive pulmonary disease (COPD). Patients and methods: This was a retrospective cohort study of 220 elderly male COPD patients (mean age 84.1 ± 6.9 years). The patients were divided into four groups on the basis of the use of β-blockers and β2-agonists. N-terminal fragment pro-B-type natriuretic peptide (NT pro-BNP), left ventricular ejection fraction (LVEF), and other relevant parameters were measured and recorded. At follow-up, the primary end point was all-cause mortality. Results: Multiple linear regression analysis revealed no significant associations between NT pro-BNP and the use of β2-agonists (β = 35.502, P = 0.905), β-blockers (β = 3.533, P = 0.989), or combination therapy (β = 298.635, P = 0.325). LVEF was not significantly associated with the use of β2-agonists (β = −0.360, P = 0.475), β-blockers (β = −0.411, P = 0.284), or combination therapy (β = −0.397, P = 0.435). Over the follow-up period, 52 patients died, but there was no significant difference in mortality among the four groups (P = 0.357). Kaplan–Meier analysis showed no significant difference among the study groups (log-rank test, P = 0.362). After further multivariate adjustment, use of β2-agonists (hazard ratio [HR] 0.711, 95% confidence interval [CI] 0.287–1.759; P = 0.460), β-blockers (HR 0.962, 95% CI 0.405–2.285; P = 0.930), or combination therapy (HR 0.638, 95% CI 0.241–1.689; P < 0.366) were likewise not correlated with mortality. Conclusion: There was no association between the use of β2-agonists, β-blockers, or β-blocker–β2-agonist combination therapy with cardiac function and all-cause mortality in elderly male COPD patients, which indicated that they may be used safely in this population. Keywords: β2-agonists, β-blockers, β-blocker–β2-agonist combination, elderly COPD patients, cardiac function, mortality
format	article
author	Zeng LH Hu YX Liu L Zhang M Cui H
author_facet	Zeng LH Hu YX Liu L Zhang M Cui H
author_sort	Zeng LH
title	Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease
title_short	Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease
title_full	Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease
title_fullStr	Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease
title_full_unstemmed	Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease
title_sort	impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/f98dddf93a9643b5b7e1aa61c245f768
work_keys_str_mv	AT zenglh impactofbeta2agonistsbetablockersandtheircombinationoncardiacfunctioninelderlymalepatientswithchronicobstructivepulmonarydisease AT huyx impactofbeta2agonistsbetablockersandtheircombinationoncardiacfunctioninelderlymalepatientswithchronicobstructivepulmonarydisease AT liul impactofbeta2agonistsbetablockersandtheircombinationoncardiacfunctioninelderlymalepatientswithchronicobstructivepulmonarydisease AT zhangm impactofbeta2agonistsbetablockersandtheircombinationoncardiacfunctioninelderlymalepatientswithchronicobstructivepulmonarydisease AT cuih impactofbeta2agonistsbetablockersandtheircombinationoncardiacfunctioninelderlymalepatientswithchronicobstructivepulmonarydisease
_version_	1718399554660859904

Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease

Ejemplares similares